Esophageal Adenocarcinoma (EAC) is a poor prognosis cancer type with rapidly rising incidence. Our 15 understanding of genetic events which drive EAC development is limited and there are few molecular 16 biomarkers for prognostication or therapeutics. We have accumulated a cohort of 551 genomically 17 characterised EACs (73% WGS and 27% WES) with clinical annotation and matched RNA-seq. Using a 18 variety of driver gene detection methods we discover 65 EAC drivers (66% novel) and describe 19 mutation and CNV types with specific functional impact. We identify a mean of 3.7 driver events per 20 case derived almost equally from copy number events and mutations. We compare driver mutation 21 rates to the exome-wide mutational excess calculated using Non-synonymous vs Synonymous 22 mutation rates (dNdS). We see mutual exclusivity or co-occurrence of events within and between a 23 number of EAC pathways (GATA factors, Core Cell cycle genes, TP53 regulators and the SWI/SNF 24 complex) suggestive of important functional relationships. These driver variants correlate with tumour 25 differentiation, sex and prognosis. Poor prognostic indicators (SMAD4, GATA4) are verified in 26 independent cohorts with significant predictive value. Over 50% of EACs contain sensitising events for 27 CDK4/6 inhibitors which are highly correlated with clinically relevant sensitivity in a panel EAC cell 28 lines. 29 30 simplest of these features is the tendency of a mutation to co-occur with other mutations in the 48 same gene at a high frequency, as detected by MutsigCV 9 . MutsigCV has been applied on several 49 occasions to EAC cohorts 6,10,11 and has identified ten known cancer genes as high confidence EAC 50 drivers (TP53, CDKN2A, SMAD4, ARID1A, ERBB2, KRAS, PIK3CA, SMARCA4, CTNNB1 and FBXW7). 51 However these analyses leave most EAC cases with only one known driver mutation, usually TP53, 52 due to the low frequency at which other drivers occur. Equivalent analyses in other cancer types 53 have identified three or four drivers per case 12,13 . Similarly, detection of copy number driver events 54 in EAC has relied on identifying regions of the genome recurrently deleted or amplified, as detected 55 by GISTIC 10,14-17 . However, GISTIC identifies relatively large regions of the genome, containing 56 hundreds of genes, with little indication of which specific gene-copy number aberrations (CNAs) may 57 actually confer a selective advantage. There are also several non-selection based mechanisms which 58 can cause recurrent CNAs, such as fragile sites where a low density of DNA replication origins causes 59 frequent structural events at a particular loci. These have not been differentiated properly from 60 selection based recurrent CNAs 18 . 61
Introduction

31
Esophageal cancer is the eighth most common form of cancer world-wide and the sixth most 32 common cause of cancer related death 1 . Esophageal Adenocarcinoma (EAC) is the predominant 33 subtype in the west, including the UK and the US. The incidence of EAC in such countries has been 34 rapidly rising, with a seven-fold increase in incidence over the last 35 years in the US 2 . EAC is a highly 35 aggressive neoplasm, usually presenting at a late stage and is generally resistant to chemotherapy, 36 leading to five-year survival rates below 15% 3 . It is characterised by very high mutation rates in 37 comparison to other cancer types 4 but also, paradoxically, there is a paucity of recurrently mutated 38 genes. EACs also display dramatic chromosomal instability and thus may be classified as a C-type 39 neoplasm which may be driven mainly by structural variation rather than mutations 5,6 . Currently our 40 understanding of precisely which genetic events drive the development of EAC is highly limited and 41 consequentially there is a paucity of molecular biomarkers for prognosis or targeted therapeutics 42 available in the clinic. 43
Driver events undergoing positive selection during cancer evolution are a small proportion 44 of total number of genetic events that occur in each tumour 7 . Methods to differentiate driver 45 mutations from passenger mutations use features associated with known driver events to detect 46 regions of the genome, often genes, in which mutations are enriched for these features 8 . The 47
Results
77
A Compendium of EAC driver events and their functional effects 78
In 551 EACs we called a total of 11,813,333 single nucleotide variants (SNVs) and small insertions or 79 deletions (Indels), with a median of 6.4 such mutations / Mb (supplementary figure 1), and 286,965 80 copy number aberrations (CNAs). We also identified 134,697 structural variants (SVs) in WGS cases. 81
Mutations or copy number variants under selection were detected using specific driver associated-82 mutation features ( Fig 1A) . We use several complementary driver detection tools to detect each 83 feature, and each tool underwent quality control to ensure reliability of results (see methods). These 84 features include highly recurrent mutations within a gene (dNdScv 21 and MutsigCV2 9 ), high 85 functional impact mutations within a gene (OncodriveFM 22 ), mutation clustering (OncodriveClust 23 , 86 eDriver 24 and eDriver3D 25 ) and recurrent amplification or deletion of genes (GISTIC 14 ) undergoing 87 concurrent over or under-expression (see methods) ( Fig 1A) 8 . 88
These complementary methods produced highly significant agreement in calling EAC driver 89 genes, particularly within the same feature-type ( Supplementary Figure 2 ) and on average more 90 than half of the genes identified by one feature were also identified by other features (Fig 1B) . In 91 total sixty five EAC driver genes were discovered, 64% of which have not been detected in EAC 92 previously 10, 11, [15] [16] [17] 19 . Of the sixty five gene identified, 82% are known drivers in pan-cancer analyses 93 giving confidence in our methods 21,26,27 . 94 EAC is notable among cancer types for harbouring a high degree of chromosomal 95 instability 20 . Using GISTIC we identified 126 recurrently deleted or amplified loci across the genome 96 (Fig 2A) . To determine which genes within these loci confer a selective advantage when they 97 undergo CNAs we use a subset of 119 cases with matched RNA-seq to detect genes within these loci 98 in which homozygous deletion or amplification causes a significant under or over-expression 99 respectively, a prerequisite for selection of CNAs. The majority of genes in these regions showed no 100 CN associated expression change (74%). We observed highly significant expression changes in 17 101 known cancer genes within GISTIC peaks such as ERBB2, KRAS and SMAD4 which we designate high-102 confidence EAC drivers. We also found five tumour suppressor genes where copy number loss was 103 not necessarily associated with expression modulation but tightly associated with presence of 104 mutations leading to LOH, for example ARID1A and CDH11. To determine whether copy number 105 changes in genes not previously associated with cancer may contribute to oncogenesis we searched 106 for genes with similar expression-CN profile as most of our high-confidence drivers (see methods). 107
We found 74 such cases which we designated "candidate copy number (CN) drivers" (supplementary 108 tables 1 and 2). Several GISTIC loci contained only one candidate driver such as ZNF131, PRKCI and 109 MYBL2 which are promising candidates for further study. 110
In a subset of GISTIC loci, we observed extremely high copy number amplification, 111 commonly greater than 100 copies, and these loci were highly correlated with presence of drivers (Wilcox test, p<Ex10 -6 ) ( Supplementary Figure 3 ). To discern a mechanism for these ultra-high 113 amplifications we assessed structural variants (SVs) associated with these events and the copy 114 number steps surrounding them. For many of these events the extreme amplification was produced 115 largely from a single copy number step the edges of which were supported by structural variants 116 with ultra-high read support. Two examples are shown in Fig2B. In the first example an inversion has 117 been followed by circularisation and amplification KRAS and in the second circularisation and 118 amplification initially occurred around MYC but subsequently incorporated ERBB2 from an entirely 119 different chromosome. A pattern of extrachromosomal amplification via double minutes has been 120 previously noted in EAC 20 , and hence we refer to this amplification class with ultra-high amplification 121
(Ploidy adjusted Copy number >10) as 'extrachromosomal-like'. Several deletion loci co-align with 122 fragile sites (Fig 2A) . Most deletion loci were dominated by heterozygous deletions while a small 123 subset had a far higher percentage of homozygous deletions including CDKN2A and several 124 associated with fragile site loci ( Fig. 2A) . For some cases we may have been unable to identify drivers 125 in loci simply because the aberrations do not occur in the smaller RNA-seq matched cohort.
We found extrachromosomal-like amplifications had an extreme and highly penetrant 127 effects on expression while moderate amplification (ploidy adjusted copy number > 2) and 128 homozygous deletion had highly significant (Wilcox test, p<Ex10 -4 and p<Ex10 -3 respectively) but less 129 dramatic effects on expression with a lower penetrance ( Fig 2C) . This lack of penetrance was 130 associated with low cellularity (fisher's exact test, expression cut off = 2.5 normalised FPKM, p<0.01) 131 in amplified cases but also likely reflects that genetic mechanisms other than gene-dosage can 132 modulate expression in a rearranged genome. We also detected several cases of over expression or 133 complete expression loss without associated CN changes which may reflect non-genetic mechanisms 134 for driver dysregulation. For example, one case overexpressed ERBB2 at 28-fold median expression 135 however had entirely diploid CN in and surrounding ERBB2 and a second case contained almost 136 complete loss of SMAD4 expression (0.008-fold median expression) despite possessing 5 copies of 137
SMAD4. 138 139
Landscape of driver Events in EAC 140
The overall landscape of driver gene mutations and copy number alterations per case is depicted in 141 Figure 3A . These comprise both oncogenes and tumour suppressor genes activated or repressed via 142 different mechanisms. Occasionally different types of events are selected for in the same gene, such 143 as KRAS which harbours both activating mutations and amplifications in 19% of cases. Passenger 144 mutations occur by chance in most driver genes. To quantify this we have used the 145 observed:expected mutation ratios (calculated by dNdScv) to estimate the percentage of driver 146 mutations in each gene and in different mutation classes. For many genes, only specific mutation 147 classes appear to be under selection. Many tumour suppressor genes; ARID2, RNF43, ARID1B for 148 example, are only under selection for truncating mutations; ie splice site, nonsense and frameshift 149
Indel mutations, but not missense mutations which are passengers. However, oncogenes, like 150 ERBB2, only contain missense drivers which form clusters to activate gene function in a specific 151 manner. Where a mutation class is <100% driver mutations, mutational clustering can help us define 152 the driver vs passenger status of a mutation (supplementary figure 4). Clusters of mutations 153 occurring in EAC or mutations on amino acids which are mutation hotspots in other cancer types 28 154 (supplementary table 3) are indicated in figure 3A . Novel EAC drivers of particular interest include 155 B2M, a core component of the MHC class I complex and resistance marker for Immunotherapy 29 , 156 MUC6 a secreted glycoprotein involved in gastric acid resistance and ABCB1 a channel pump protein 157 which is associated with multiple instances of drug resistance 30 . Lollipop plots showing primary 158 sequence distribution of mutations in these genes are provided (supplementary data). 159
The identification of driver events provides a rich information about the molecular history of 160 each EAC tumour. We detect a median of four events in driver genes per tumour (IQR = 3-6, Mean = 161 5.1) and only a very small fraction of cases have no such events detected (11 cases, 2%). When we 162 remove the predicted percentage of passenger mutations using dnds ratios we find a mean of 3.7 163 true driver events per case which derive quite evenly from both copy number events and mutations 164 ( Fig 3B) . dNdScv, one of the driver gene detection methods used, also analyses the genome-wide 165 excess of non-synonymous mutations based on expected mutation rates to assess the total number 166 of driver mutations across the exome which is calculated at 4.8 (95% CIs: 3.7-5.9) in comparison to 167 2.1 driver mutations which we calculate in our gene-centric analysis after passenger removal. This 168 suggests low frequency driver genes may be prevalent in the EAC mutational landscape (see 169 discussion). Further analysis suggests these missing mutations are mostly missense mutations and 170 our gene-centric analysis captures almost all predicted splice and nonsense drivers (Supplementary 171 Figure 5 ). Some of our methods use enrichment of nonsense and splice mutations as a marker of 172 driver genes and hence have a higher sensitivity for these mutations. 173
To better understand the functional impact of driver mutations we analysed expression of 174 driver genes with different mutation types and compared their expression to normal tissue RNA, 175 which was sequenced alongside our tumour samples ( Figure 3C ). Since surrounding squamous epithelium is a fundamentally different tissue, from which EAC does not directly arise, we have used 177 duodenum and gastric cardia samples as gastrointestinal phenotype controls, likely to be similar to 178 the, as yet unconfirmed, tissue of origin in EAC. A large number of driver genes have upregulated 179 expression in comparison to normal controls, for example TP53 has upregulated RNA expression in 180 WT tumour tissue and in cases with missense (non-truncating) mutations but RNA expression is lost 181 upon gene truncation. In depth analysis of different TP53 mutation types reveals significant 182 heterogeneity within non-truncating mutations, for example R175H mutations correlate with low 183 RNA expression (supplementary figure 6 ). Normal tissue expression of CDKN2A suggests that 184 CDKN2A is generally activated in EAC and returns to physiologically normal levels when deleted. 185
Heterogeneous expression in WT CDKN2A cases suggest a different mechanism of inhibition such as 186 methylation in some cases. Overexpression of other genes in wild type tumours, such as SIN3A, may 187 be a confer selective advantage due to their oncogenic properties, in this case cooperating with 188 MYC, which is also overexpressed in EACs ( Fig 3C) . A smaller number of driver genes are 189 downregulated in EAC tissue-3/4 of these (GATA4, GATA6 and MUC6) are involved in the 190 differentiated phenotype of gastrointestinal tissues and may be lost with tumour de-differentiation. 191 Driving alterations in these genes have been observed in other GI cancers 13,31,32 however their 192 oncogenic mechanism is unknown. In most genes we did not observe expression loss at the RNA 193 level with truncation, for instance ARID1A (supplementary figure 7) . 194
195
Dysregulation of specific pathways and processes in EAC 196
It is known that selection preferentially dysregulates certain functionally related groups of genes and 197 biological pathways in cancer 33 . This phenomenon is highly evident in EAC, as shown in Figure 4 While TP53 is the dominant driver in EAC, 30% of cases remain TP53 wildtype. MDM2 is a E3 201 ubiquitin ligase that targets TP53 for degradation. Its selective amplification and overexpression is 202 mutually exclusive with TP53 mutation suggesting it can functionally substitute the effect of TP53 203 mutation via its degradation. Similar mutually exclusive relationships are observed between; KRAS 204 and ERBB2, GATA4 and GATA6 and Cyclin genes (CCNE1, CCND1 and CCND3). Activation of the Wnt 205 pathway occurs in 19% of cases either by mutation of phospho-residues at the N terminus of -206 catenin, which prevent degradation, or loss of Wnt destruction complex components like APC. Many 207 different chromatin modifying genes, often belonging to the SWI/SNF complex, are also selectively 208 mutated (31% of cases). In contrast SWI/SNF genes are co-mutated significantly more often than we 209 would expect by chance (fisher's exact test, p<0.01 see methods), suggesting an increased advantage 210 to further mutations once one has been acquired. We also assessed mutual exclusivity and co-211 occurrence in genes in different pathways and between pathways themselves ( Figure 4B ). Of 212 particular note are co-occurring relationships between TP53 and MYC, GATA6 and SMAD4, Wnt and 213
Immune pathways as well as mutually exclusive relationships between ARID1A and MYC, 214 gastrointestinal (GI) differentiation and RTK pathways and SWI-SNF and DNA-Damage response 215 pathways. We were able to confirm some of these relationships in independent cohorts in different 216 cancer types (supplementary table 4) suggesting some of these may be pan-cancer phenomenon. As 217 shown in figure 3, all of these pathways interact to stimulate the G1 to S phase transition of the cell 218 cycle via promoting phosphorylation of Rb, although many of these pathways have multiple 219 oncogenic or tumour suppressive functions. 220 A number of other driver genes have highly related functional roles including core 221 transcriptional components (TAF1 and POLQ), drivers of immune escape (JAK1 and B2M 29 ), cell 222 adhesion receptors (CDH1, CHDL and PCDH17), core ribosome components (ELF3 and RPL22), core 223 RNA processing components (GPATCH8 and COIL), ion channels (KCNQ3 and TRPA1) and Ephrin 224 type-A receptors (EPHA2 and EPHA3).
Clinical significance of driver variants 226
Events undergoing selection during cancer evolution influence tumour biology and thus impact 227 tumour aggressiveness, response to treatment and patient prognosis as well as other clinical 228 parameters. Clinical-genomic correlations can provide useful biomarkers but also give insights into 229 the biology of these events. 230
Univariate Cox regression was performed for events in each driver gene with driver events 231 occurring in greater than 5% of EACs (ie after removal of predicted passengers, 16 genes) to detect 232 prognostic biomarkers ( Fig 5A) . Events in two genes conferred significantly poorer prognosis after 233 multiple hypothesis correction, GATA4 (HR : 0.54 , 95% CI : 0.38 -0.78, P value = 0.0008) and SMAD4 234 (HR : 0.60 , 95% CI : 0.42 -0.84, P value = 0.003). Both genes remained significant in multivariate Cox 235 regression including pathological tumour stage (GATA4 = HR adjusted : 0.63, 95% CIs adjusted : 0.40 236 -0.98, P value = 0.042 and SMAD4 = HR adjusted : 0.63, 95% CI adjusted : 0.41 -0.97, P value = 237 0.038). 31% of EACs contain either SMAD4 mutation or homozygous deletion or GATA4 amplification 238 and cases with both genes altered had a poorer prognosis (figure 5B). We validated the poor 239 prognostic impact of SMAD4 events in an independent TCGA gastroesophageal cohort (HR = 0.58, 240 95% CI = 0.37 -0.90, P value =0.014) ( Fig 5C) and we also found GATA4 amplifications were 241 prognostic in a cohort of TCGA pancreatic cancers (HR = 0.38 95% CI: 0.18 -0.80, P value = 0.011) 242 ( Fig 5D) , the only available cohort containing a feasible number of GATA4 amplifications. The 243 prognostic impact of GATA4 has been suggested in previously published independent EAC cohort 16 244 although it did not reach statistical significance after FDR correction and SMAD4 expression loss has 245 been previously linked to poor prognosis in EAC 34 . We also noted stark survival differences between 246 cases with SMAD4 events and cases in which TGF receptors were mutated (Fig 5E, HR = 5.6, 95% CI 247 : 1.7 -18.2, P value = 0.005) in keeping with the biology of the TGF pathway where non-SMAD 248 TGF signalling is known to be oncogenic 35 . 249 In additional to survival analyses we also assessed driver gene events for correlation with 250 various other clinical factors including differentiation status, sex, age and treatment response. We 251 found Wnt pathway mutations had a strong association with well differentiated tumours (p=0.001, 252 OR = 2.9, fisher's test, see methods, Fig 5F) . We noted interesting differences between female 253 (n=81) and male (n=470) cases. Female cases were enriched for KRAS mutation (p = 0.001, fisher's 254 exact test) and TP53 wildtype status (p = 0.006, fisher's exact test) ( Fig 5G) . This is of particular 255 interest given the male predominance of EAC 3 . 256 257 Targeted therapeutics using EAC driver events. 258
The biological distinctions between normal and cancer cells provided by driver events can be used to 259 derive clinical strategies for selective cancer cell killing. To investigate whether the driver events in 260 particular genes and/or pathways might sensitise EAC cells to certain targeted therapeutic agents 261 we used the Cancer Biomarkers database 36 . We calculated the percentage of our cases which 262 contain EAC-driver biomarkers of response to each drug class in the database (summary shown Fig  263   6A , and full data supplementary table 5). Aside from TP53, which has been problematic to target 264 clinically so far, we found a number of drugs with predicted sensitivity in >10% of EACs including 265 EZH2 inhibitors for SWI/SNF mutant cancers (23% and 33% including other SWI/SNF EAC 266 drivers), and BET inhibitors which target KRAS activated and MYC amplified cases (25%). However, 267 by far the most significantly effective drug was predicted to be CDK4/6 inhibitors where >50% of 268 cases harboured sensitivity causing events in the receptor tyrosine kinase (RTK) and core cell cycle 269 pathways (eg in CCND1, CCND3 and KRAS). 270
To verify that these driver events would also sensitise EAC tumours to such inhibitors we 271 used a panel of eight EAC cell lines which have undergone whole genome sequencing 37 and assessed 272 them for presence of EAC driver events ( Figure 6B ). The mutational landscape of these lines was 273 broadly representative of EAC tumours. We found that the presence of cell cycle and or RTK activating driver events was highly correlated with response to two FDA approved CDK4/6 inhibitors, 275
Ribociclib and Palbociclib and several cell lines were sensitive below maximum tolerated blood 276 concentrations in humans ( Figure 6B , supplementary table 6, Supplementary Figure 8 ) 38 . Such EAC 277 cell lines had comparable sensitivity to T47D which is derived from an ER +ve breast cancer where 278 CDK4/6is have been FDA approved. We noted three cell lines without sensitising events which were 279 highly resistant, with little drug effect even at 4000nM concentrations, similar to a known Rb mutant 280 resistant line breast cancer cell line (MDA-MB-468). Two of these three cell lines harbour 281 amplification of CCNE1 which is known to drive resistance to CDK4/6i by bypassing CDK4/6 and 282 causing Rb phosphorylation via CDK2 activation 39 . 283 284 Discussion 285 We present here a detailed catalogue of events that have been selected for during the evolution of 286 esophageal adenocarcinoma. These events have been characterised in terms of their relative impact, 287 related functions, mutual exclusivity and co-occurrence and expression in comparison to normal 288 tissues, producing insights into EAC biology. We have used this set of biologically important gene 289 alterations to identify prognostic biomarkers and actionable genomic events for personalised 290 medicine. 291
While clinical annotation and matched RNA data is a strength of this study, in some cases we 292 may have been unable to assess selected variants for survival associations or expression changes 293 which were detected in the full 551 cohort, due to lack of representation in clinically annotated or 294 RNA matched sub cohorts. Despite rigorous analyses to detect selected events, assessment of the 295 global excess of mutations by dNdScv suggests we are unable to detect all events selected in EAC, 296 similar to many other cancer types 21 . All driver gene detection methods which we have used rely on 297 driver mutation re-occurrence in a gene to some degree. Many of these undetected driver 298 mutations are hence likely to be spread across a large number of genes whereby each is mutated at 299 low frequency across EAC patients. This tendency for low frequency EAC drivers may be responsible 300 for the low yield of MutsigCV in previous cohorts and may suggests that C-type cancers such as EAC, 301 are not less 'mutation-driven' than M-type cancers but rather that their mutational drivers are 302 spread across a larger number of genes 5 . The identification of these very low frequency mutations 303 will require substantially different detection techniques to those which are currently in wide spread 304 use and such methods are in development 40 although they require validation. Undoubtedly many 305 copy drivers are also left undiscovered and validation of candidates identified here is an important 306 avenue of future work. 307
While a number of previous reports have attempted to detect EAC drivers, they have had a 308 limited yield per case for a variety of reasons. The first such study 19 used methods which, despite 309 being well regarded at the time, were subsequently discredited 9 . Hence a number of known false 310 positive genes (EYS, SYNE1 and CNTTAP5) were erroneously reported as drivers, along with an 311 additional unknown number of genes. Since then a number of reports, including our own, on 312 medium and large cohort sizes using MutsigCV 10,11,17 were only able to detect a small number of 313 mutational driver genes (7, 5 and 15 in each study). By using both a large cohort and more 314 comprehensive methodologies we have significantly increased this figure to 52 mutational driver 315 genes (excluding CN drivers). Detection of driver CNAs has previously relied on GISTIC to detect 316 recurrently mutated regions 10,14-17 but no analyses have been performed to evidence which genes in 317 these large regions are true drivers. Many of the genes annotated by such papers are unlikely to be 318 CN drivers from this analysis due to their lack of expression modulation with CNAs (eg YEATS4 and 319 MCL1), the role of recurrent heterozygous losses to drive LOH in some mutational drivers (ARID1A 320 and CDH11) or their association with fragile sites (PDE4D, WWOX, FHIT). Conversely, we have been 321 able to identify novel EAC copy number drivers (eg CCND3, AXIN1 and APC). 322
A number of discoveries made in this work require further investigation. Functional 323 characterisation of many of the driver genes described is needed to understand why they are 324 advantageous to EAC tumours and how they modify EAC biology. Particularly interesting are the GI 325 specific genes GATA4/6 and MUC6 which modulate prognosis and have expression loss during the 326 transition from normal to tumour tissue. Biological pathways and processes that are selectively 327 dysregulated deserve particular attention in this regard as do the gene pairs or groups with mutually 328 exclusive or co-occurring relationships such as MYC and TP53 or SWI/SNF factors, suggestive of 329 particular functional relationships. Prospective clinical work to verify and implement SMAD4 and 330 GATA4 biomarkers in this study would be worthwhile. While whole genome or whole exome 331 sequencing may be impractical for use in the clinic, targeted NGS panels to detect mutations and 332 copy number alterations have been implemented to detect genomic biomarkers in a cost effective 333 and sensitive manner for some cancer types 41 . In EAC development of a customised panel is likely to 334 be required on the basis of this analysis. A number of targeted therapeutics may provide clinic 335 benefit to EAC cases based on their individual genomic profile. In particular CDK4/6 inhibitors 336 deserve considerable attention as an option for EAC treatment as they are, by a significant margin, 337 the treatment to which the most EACs harbour sensitivity-causing driver events, excluding TP53 as 338 an unlikely therapeutic biomarker. The in vitro validation of these biomarkers for CDK4/6 inhibitors 339 in EAC is also persuasive of possible clinical benefit using a targeted approach. 340
In summary this work provides a detailed compendium of mutations and copy number 341 ratios to estimate the probability of a particular mutation being a driver. In this case the dnds ratio 485 suggests 2/3 of missense mutations are drivers hence 10/15. 7 missense mutation lie in a mutational 486 cluster, in this case of known significance in the N-terminal of B-Catenin, making it likely that these 487 are drivers and a most (5/7) other mutations are passengers. Similarly, mutations on amino acids 488 known to be hyper mutated in other cancer types (see Supplementary table 3, for instance if we  489 found a single KRAS G12 mutation) can be considered likely drivers. 490
Supplementary Figure 5 . A detailed breakdown of mutation and copy number types per case and a 492 breakdown of exome wide dnds excess for different mutation types (note that exome wide indel 493 cannot be calculated excess as they have no synonymous mutation equivalent, although a null 494 model is used in the per gene dnds method to use them to detect driver genes). run through our alignment (BWA-MEM), mutation (Strelka) and copy number (ASCAT) and structural 518 variant (Manta) calling pipelines, as previously described 17 . Our methods were benchmarked against 519 various other available methods and have among the best sensitivity and specificity for variant 520 calling (ICGC benchmarking excerise 42 ). Mutation and copy number calling on cell lines was 521 performed as previously described 37 . 522 Total RNA was extracted using All Prep DNA/RNA kit from Qiagen and the quality was checked on 523 Agilent 2100 Bioanalyzer using RNA 6000 nano kit (Agilent). Qubit High sensitivity RNA assay kit from 524 thermo fisher was used for quantification. Libraries were prepared from 250ng RNA, using TruSeq 525
Stranded Total RNA Library Prep Gold (Ribo-zero) kit and ribosomal RNA (nuclear, cytoplasmic and 526 mitochondrial rRNA) was depleted, whereby biotinylated probes selectively bind to ribosomal RNA 527 molecules forming probe-rRNA hybrids. These hybrids were pulled down using magnetic beads and 528 rRNA depleted total RNA was reverse transcribed. The libraries were prepared according to Illumina 529 protocol 43 . Paired end 75bp sequencing on HiSeq4000 generated the paired end reads. 530 531
Analysing EAC mutations for selection 532
To detect positively selected mutations in our EAC cohort, a multi-tool approach across various 533 selection related 'Features' (Recurrance, Functional impact, Clustering) was implemented in order to 534 provide a comprehensive analysis. This is broadly similar to several previous approaches 8, 44 . 535 dNdScv 21 , MutsigCV 9 , e-Driver 24 and e-Driver3D 25 were run using the default parameters. To run 536
OncodriverFM 22 , Polyphen 45 and SIFT 46 were used to score the functional impact of each missense 537 non-synonomous mutation (from 0, non-impactful to 1 highly impactful), synonymous mutation were given a score of 0 impact and truncating mutations (Non-sense and frameshift mutations) were 539 given a score of 1. Any gene with less than 7 mutations, unlikely to contain detectable drivers using 540 this method, was not considered to decrease the false discovery rate. OncodriveClust was run using 541 a minimum cluster distance of 3, minimum number of mutations for a gene to be considered of 7 542 and with a stringent probability cut off to find cluster seeds of p = Ex10 -13 to prevent infiltration of 543 large numbers of, likely, false positive genes. For all tool outputs we undertook quality control 544 including Q-Q plots to ensure no tool produces inflated q-values and each tool produced at least 545 30% known cancer genes. Two tools were removed from the analysis due to failure for both of these 546 parameters at quality control (Activedriver 47 and Hotspot 28 ). For three of the QC-approved tools 547 (dNdScv, OncodriveFM, MutsigCV) where this was possible we also undertook an additional fdr 548 reducing analysis by re-calculating q values based on analysis of known cancer genes only 21, 26, 27 as 549 has been previously implemented 21, 48 . Tool outputs were then put through various filters to remove 550 any further possible false positive genes. Specifically, genes where <50% of EAC cases had no 551 expression (TPM<0.1) in our matched RNA-seq cohort were removed and, using dNdScv, genes with 552 no significant mutation excess (observed: expected ratio > 2:1) of any single mutation type were also 553 removed (8 genes). We also removed two (MT-MD2, MT-MD4) mitochondrial genes which were 554 highly enriched for truncating mutations and were frequently called in OncodriveFM as well as other 555 tools. This is may be due to the different mutational dynamics, caused by ROS from the 556 mitochondrial electron transport chain, and the high number of mitochondrial genomes per cell 557 which enables significantly more heterogeneity. These factors prevent the tools used from 558 calculating an accurate null model for these genes however they may be worthy of functional 559 investigation. 560 561 562 563
Detecting selection in CNVs 564
ASCAT raw CN values were used to detected frequently deleted or amplified regions of the genome 565 using GISTIC2.0 14 . To determine which genes in these regions confer a selective advantage, CNVs 566 from each gene within a GISTIC identified loci were correlated with FPKM from matched RNA-seq in 567 a sub-cohort of 119 samples and with mutations across all 551 samples. To call copy number in 568 genes which spanned multiple copy number segments in ASCAT we considered the total number of 569 full copies of the gene (ie the lowest total copy number). Occasionally ASCAT is unable to confidently 570 call the copy number in a highly aberrant genomic regions. We found that the expression of genes in 571 such regions matched well what we would expect given the surrounding copy number and hence we 572 used the mean of the two adjacent copy number fragments to call copy number in the gene in 573 question. We found amplification peak regions identified by GISTIC2.0 varied significantly in precise 574 location both in analysis of different sub-cohorts and when comparing to published GISTIC data from 575 EACs 10,15,16 . A peak would often sit next to but not overlapping a well characterised oncogene or 576 tumour suppressor. To account for this, we widened the amplification peak sizes upstream and 577 downstream by twice the size of each peak to ensure we captured all possible drivers. Our 578 expression analysis allows us to then remove false positives from this wider region and called drivers 579 were still highly enriched for genes closer to the centre of GISTIC peak regions. 580
To detect genes in which amplification correlated with increased expression we compared 581 expression of samples with a high CN for that gene (top 25% percentile of CN) with those which have 582 a normal CN (median +/-1) using the Wilcox rank-sum test and using the specific alternative 583 hypothesis that high CN would lead to increased expression. Q-values were then generated based on 584
Benjamini & Hochberg method, not considering genes without significant expression in amplified 585 samples (at least 80% amplified samples with FPKM > 1) and considering q<0.001 as significant. We 586 also included an additional known driver gene only FDR reduction analysis as previously described 587 for mutational drivers with q<0.05 considered as significant given the additional evidence for these 588 genes in other cancer types. We took the same approach to detect genes in which homozygous 589 deletion correlated with expression loss. Expression modulation was a highly specific marker for 590 known CN driver genes and was not a widespread feature in most recurrently copy number variant 591 genes. However, while expression modulation is a requirement for selection of CNV only drivers, it is 592 not sufficient evidence alone and hence we grouped such genes into those which have been 593 characterised as drivers previously in other cancer types (high confidence EAC CN drivers) and other 594 genes (Candidate EAC CN drivers) which await functional validation. We used fragile site regions 595 detected in Wala et al 2017 49 . We also defined regions which may be recurrently heterozygous 596 deleted, without any significant expression modulations, to allow LOH of tumour suppressor gene 597 mutations. To do this we analyses genes with at least 5 mutations in the matched RNA cohort for 598 association between LOH (ASCAT minor allele = 0) and mutation using fisher's exact test and 599 generated q values using the Benjamini & Hochberg method. The analysis was repeated on known 600 cancer genes only for reduced FDR and q < 0.05 considered significant for both analyses. For those 601 high confidence drivers we chose to define amplification as CN/ploidy (referred to as Ploidy adjusted 602 copy number) this produces superior correlation with expression. We chose a cut off for 603 amplification at CN/ploidy = 2 as has been previously used, and as causes a highly significant 604 increase in expression in our CN-driver genes. 605 606
Pathways and relative distributions of genomic events 607
The relative distribution of driver events in each pathway was analysed using a fisher's exact test in 608 the case of pair-wise comparisons including WT cases. In the case of multi-gene comparisons such as 609 the Cyclins we calculate the p value and odds ratio for each pair in the group by fisher's exact test 610 and combine p values using the Fisher method, Genes without comparable Odds ratios to the rest of 611 the genes in question were removed. For this analysis we also remove highly mutated cases (>500 612 exonic mutations, 41/551) as they bias distribution of genes towards co-occurrence. We repeated 613 this analyses across all pairs of driver genes using BH multiple hypothesis correction. We validated 614 these relationships in independent TGCA cohorts of other GI cancers where we could find cohorts 615 with reasonable numbers of the genomic events in question (not possible for GATA4/6 for instance) 616 using the cBioportal web interface tool 50 . 617 618
Correlating genomics with the clinical phenotype 619
To find genomic markers for prognosis we undertook univariate Cox regression for those driver 620 genes present in >5% of cases (16) along with Benjamini & Hochberg false discovery correction. We 621 considered only these genes to reduce our false discover rate and because other genes were unlikely 622 to impact on clinical practise given their low frequency in EAC. We validated SMAD4, in the TCGA 623 gastroesophageal cohort which had a comparable frequency of these events, but notably is 624 composed mainly of gastric cancers, and GATA4 in the TCGA pancreatic cohort using the cBioportal 625 web interface tool. We also validated these markers as independent predictors of survival both in 626 respect of each other and stage using a multivariate Cox regression in our 551 case cohort. When 627 assessing for genomic correlates with differentiation phenotypes we found only very few cases with 628 well differentiated phenotypes (<5% cases) and hence for statistical analyses we collapse these cases 629 with moderate differentiation to allow a binary fisher's exact test to compare poorly differentiated 630 with well-moderate differentiated phenotypes. 631 632 Therapeutics 633
The cancer biomarker database was filtered for drugs linked to biomarkers found in EAC drivers and 634 supplementary table 6 constructed using the cohort frequencies of EAC biomarkers. 8 EAC cell lines 635 with WGS data 37 were used in proliferation assays to determine drug sensitivity to CDK4/6 inhibitors, 636 Palbociclib (Biovision) and Ribociclib (Selleckchem). Cell lines were grown in their normal growth media (methods table 1). Proliferation was measured using the Incucyte live cell analysis system 638 (Incucyte ZOOM Essen biosciences). Each cell line was plated at a starting confluency of 10% and 639 growth rate measured across 4-7 days depending on basal proliferation rate. For each cell-line drug 640 combination concentrations of 16, 64, 250, 1000 and 4000nM were used each in 0.3% DMSO and 641 compared to 0.3% DMSO only. Each condition was performed in at least triplicate. The time period 642 of the exponential growth phase in the untreated (0.3% DMSO) condition was used to calculate GI50 643 and AUC. Accurate GI50s could not be calculated in cases where a cell line had >50% proliferation 644 inhibition even with the highest drug concentration and hence AUC was used to compare cell line 645 sensitivity. T47D had a highly similar GI50 for Palbociclib to that previously calculated in other 646 studies (112 nM vs 127 nM) 51 0  10  20  30  40  50  60  70  80  90  10 0  110  120  130  140  150  160  170  180  190   chr4   0  10  20  30  40  50  60  70  80  90  100  110  120  130  140  150  160  170 TP53  CDKN2A  KRAS  MYC  ERBB2  GATA4  GATA6  SMAD4  CDK6  CCND1  ARID1A  CCNE1  EGFR  CCND3  MUC6  MDM2  SMARCA4  KCNQ3  APC  PIK3CA  PTEN  ABCB1  RNF43  MET  SPG20  TRPA1  EPHA3  CRISPLD1  AXIN1  FBXW7  ACVR2A  ARID2  RASA1  LIN7A  COIL  PBRM1  ARID1B  CTNNB1  DNAH7  MAP2K7  PIK3R1  RPL22  NIPBL  B2M  HIST1H3B  MBD6  TGFBR2  SIN3A  CDH1  EPHA2  MSH3  CDKN1B  ACVR1B  STK11  POLQ  JAK1  BRAF  FAM196B  CHL1  GPATCH8  MAP3K1  NUMA1  PCDH17  KDM6A Amplification is defined as >2 Copy number adjusted ploidy (2 x ploidy of that case) and extrachromosomal amplification as >10 Copy number adjusted ploidy (10 x ploidy for that case). Driver associated features for each driver gene are displayed to the left. On the right the percentages of different mutation and copy number changes are displayed, differentiating between driver and passenger mutations using dNdScv, and the % of predicted drivers by mutation type is shown. Above the plot are the number of driver mutations per sample with an indication of the median (red line = 4). b. Assessment of driver event types per case and comparison to exome-wide excess of mutations generated by dNdScv. c. Expression changes in EAC driver genes in comparison to normal intestinal tissues. Only genes with signifcant expression changes of note are shown. Drug classes for which sensitivity is indicated by EAC driver genes with data from the Cancer Biomarkers database36. b. Area under the curve (AUC) of sensitivity is shown in a panel of 8 EAC cell lines with associated WGS and driver event, based in tumour analysis, in these cell lines indicated. Also AUC is shown for two control lines T47D, an ER +ve breast cancer line (+ve control) and MDA-MB-468 a Rb negative breast cancer (-ve control). *CCNE1 is a known marker of resistance to CDK4/6is due to its regulation of Rb downstream of CDK4/6 hence bypassing the need for CDK4/6 activity (see figure 4 ).
